Ovid Therapeutics (OVID) EBIAT (2020 - 2025)
Historic EBIAT for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to -$12.2 million.
- Ovid Therapeutics' EBIAT rose 1289.45% to -$12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$36.4 million, marking a year-over-year decrease of 1195.96%. This contributed to the annual value of -$26.4 million for FY2024, which is 4949.66% up from last year.
- As of Q3 2025, Ovid Therapeutics' EBIAT stood at -$12.2 million, which was up 1289.45% from -$4.7 million recorded in Q2 2025.
- In the past 5 years, Ovid Therapeutics' EBIAT ranged from a high of $176.0 million in Q1 2021 and a low of -$26.0 million during Q4 2021
- Over the past 5 years, Ovid Therapeutics' median EBIAT value was -$12.0 million (recorded in 2022), while the average stood at -$2.0 million.
- As far as peak fluctuations go, Ovid Therapeutics' EBIAT soared by 97871.45% in 2021, and later plummeted by 15515.78% in 2025.
- Ovid Therapeutics' EBIAT (Quarter) stood at -$26.0 million in 2021, then skyrocketed by 55.75% to -$11.5 million in 2022, then crashed by 33.18% to -$15.3 million in 2023, then surged by 39.61% to -$9.3 million in 2024, then tumbled by 31.85% to -$12.2 million in 2025.
- Its last three reported values are -$12.2 million in Q3 2025, -$4.7 million for Q2 2025, and -$10.2 million during Q1 2025.